Intravesical Disitamab Vedotin (RC48) for HER2‐Expressing High‐Risk Non‐Muscle‐Invasive Bladder Cancer: A Single‐Arm, Dose–Escalation Phase I Trial Study

ABSTRACT HER2 expression is correlated with diminished efficacy of Bacillus Calmette–Guérin (BCG) instillation in high‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC). The development of effective intravesical treatments for HER2‐expressing HR‐NMIBC is of great urgency. In this single‐arm phase I...

Cur síos iomlán

Sonraí bibleagrafaíochta

Príomhchruthaitheoirí:	Xu Chen, Ming Huang, Zehua Chen, Chengjunyu Zhang, Bolin Pan, Chu Liu, Wentong Xu, Jianmin Fang, Jian Huang, Tianxin Lin
Formáid:	Artigo
Teanga:	Inglês
Foilsithe / Cruthaithe:	Wiley 2025-07-01
Sraith:	MedComm
Ábhair:	antibody‒drug conjugates (ADC) Disitamab vedotin (RC48) efficacy intravesical non‐muscle‐invasive bladder cancer safety
Rochtain ar líne:	https://doi.org/10.1002/mco2.70288
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!